Search

Displaying results 1741 - 1750 of 6076 in total
  1. Drug

    Roflumilast

    go.drugbank.com/drugs/DB01656
    ApprovedInvestigational

    [L46541] On December 15, 2023, the FDA approved a new topical foam formulation of roflumilast for the treatment of seborrheic dermatitis in patients aged 9 years and older.[L49281]

    Categories: Antipsoriatics for Topical Use, Drugs for Obstructive Airway Diseases
  2. Drug

    Aprepitant

    go.drugbank.com/drugs/DB00673
    ApprovedInvestigational

    Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV). … Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting

  3. Drug

    Lanadelumab

    go.drugbank.com/drugs/DB14597
    ApprovedInvestigational

    Lanadelumab, also known as DX-2930, is a human IgG1 monoclonal antibody designed for subcutaneous self-injection. … [L4537] It has been granted priority review, breakthrough therapy, and orphan drug designations for rare diseases based on the results of clinical trials.

  4. Drug

    Dengue virus serotype 4

    go.drugbank.com/drugs/DB22667
    Approved

    [L53368] Qdenga was approved for use in the European Union in December 2022.[L53373] … [A274008] It is one of four serotypes covered by Qdenga, a live, attenuated, tetravalent vaccine used for the prevention of dengue disease.

  5. Drug

    DFV890

    go.drugbank.com/drugs/DB16461
    Investigational

    DFV890 is under investigation in multiple clinical trials for its efficacy, safety, and tolerability across various conditions: NCT06031844 (coronary heart disease with elevated hsCRP), NCT04886258 (symptomatic

    Categories: Experimental Unapproved Treatments for COVID-19
  6. Drug

    MPT0B640

    go.drugbank.com/drugs/DB16512
    Investigational

    MPT0B640 was under investigation in clinical trials NCT04526717 for COVID-19 infection and NCT04294875 for locally advanced or metastatic solid malignancies.

    Categories: Experimental Unapproved Treatments for COVID-19
  7. Drug

    Primaquine

    go.drugbank.com/drugs/DB01087
    ApprovedInvestigational

    It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria.

    Categories: Antibiotics for Pneumocystis Pneumonia
  8. Drug

    Propanoic acid

    go.drugbank.com/drugs/DB03766
    ApprovedInvestigationalVet approvedWithdrawn

    It is considered generally recognized as safe (GRAS) food ingredient by FDA, where it acts as an antimicrobial agent for food preservation and flavoring agent.

  9. Drug

    Tenofovir alafenamide

    go.drugbank.com/drugs/DB09299
    ApprovedInvestigational

    [T239] Tenofovir alafenamide is an alanine ester form characterized for presenting low systemic levels but high intracellular concentration.

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  10. Drug

    CTS-21166

    go.drugbank.com/drugs/DB06073
    Investigational

    CTS-21166 is the only BACE1 inhibitor that has passed Phase I clinical trial thus far. … CTS-21166 is a small-molecule beta-secretase inhibitor, which is being developed as a disease-modifying treatment for Alzheimer's disease.